Condition: Hypogammaglobulinemia · Autoimmune Conditions · Rheumatic Conditions · Sponsor: Octapharma
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
This description comes directly from the study's public registry record.
Patrick Murphy · 413-821-0022 · p.murphy@crmg-usa.com
Always discuss trial participation with your own doctor first.
| Perseverance Research Center, Phoenix Neurological Associates | Scottsdale, Arizona, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07220915